Smith Group Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Smith Group Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,344	Closed	-$179K	–	511
2016 Q1	$179K	Sell	3,344 -100	-3%	-$5.87K	0.01%	241
2015 Q4	$226K	Hold	3,444	–	–	0.01%	224
2015 Q3	$194K	Hold	3,444	–	–	0.01%	224
2015 Q2	$204K	Sell	3,444 -890	-21%	-$54.9K	0.01%	216
2015 Q1	$270K	Hold	4,334	–	–	0.01%	257
2014 Q4	$249K	Sell	4,334 -208	-5%	-$11.6K	0.01%	259
2014 Q3	$244K	Buy	4,542 +208	+5%	+$11K	0.01%	217
2014 Q2	$227K	Buy	+4,334	New	+$222K	0.01%	225

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Smith Group Asset Management's TEVA Position: Q2 2016 in Review

Smith Group Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 3,344 shares — an estimated $179K sold.

Smith Group Asset Management first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $270K in Q1 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Smith Group Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Smith Group Asset Management sold 3,344 Teva Pharmaceuticals shares in Q2 2016, an estimated $179K.
Smith Group Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Smith Group Asset Management's Teva Pharmaceuticals position peaked at $270K in Q1 2015.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Smith Group Asset Management's 13F filing for Q2 2016, filed 26 Jul 2016.